Application of urine antigen assay to evaluate outcomes of praziquantel treatment and reinfection in opisthorchiasis in northeast Thailand.


Journal

Transactions of the Royal Society of Tropical Medicine and Hygiene
ISSN: 1878-3503
Titre abrégé: Trans R Soc Trop Med Hyg
Pays: England
ID NLM: 7506129

Informations de publication

Date de publication:
05 10 2020
Historique:
received: 10 03 2020
revised: 25 05 2020
accepted: 02 07 2020
pubmed: 1 8 2020
medline: 29 5 2021
entrez: 1 8 2020
Statut: ppublish

Résumé

A urine antigen assay was applied to evaluate chemotherapeutic outcomes and reinfection patterns of opisthorchiasis in Thailand. We used a prospective study design by following opisthorchiasis subjects at baseline and post-treatment using a urine antigen assay and faecal examination by the formalin-ethyl acetate concentration technique (FECT). The antigen of Opisthorchis viverrini in urine diminished within 4 weeks after praziquantel treatment. Concurrent faecal examinations by FECT showed that faecal eggs were negative at 4 weeks after treatment. In a subsequent study, reinfection rates and intensity patterns of O. viverrini were evaluated at 48 weeks after praziquantel treatment. Within a group of subjects with curative treatment (n=137), 16.8% became reinfected according to FECT and 27.7% according to the urine antigen assay (p<0.05). There were significant correlations in intensity of infection between pretreatment and at 48 weeks post-treatment in both faecal egg counts and antigen levels in urine. The results suggested that in addition to screening, the urine antigen assay is an efficient tool for monitoring outcomes of drug treatment and reinfection in opisthorchiasis. Due to the ease of urine sample collection and handling, the urine assay becomes an alternative method to faecal examination for diagnosis and monitoring of opisthorchiasis.

Sections du résumé

BACKGROUND
A urine antigen assay was applied to evaluate chemotherapeutic outcomes and reinfection patterns of opisthorchiasis in Thailand.
METHODS
We used a prospective study design by following opisthorchiasis subjects at baseline and post-treatment using a urine antigen assay and faecal examination by the formalin-ethyl acetate concentration technique (FECT).
RESULTS
The antigen of Opisthorchis viverrini in urine diminished within 4 weeks after praziquantel treatment. Concurrent faecal examinations by FECT showed that faecal eggs were negative at 4 weeks after treatment. In a subsequent study, reinfection rates and intensity patterns of O. viverrini were evaluated at 48 weeks after praziquantel treatment. Within a group of subjects with curative treatment (n=137), 16.8% became reinfected according to FECT and 27.7% according to the urine antigen assay (p<0.05). There were significant correlations in intensity of infection between pretreatment and at 48 weeks post-treatment in both faecal egg counts and antigen levels in urine.
CONCLUSIONS
The results suggested that in addition to screening, the urine antigen assay is an efficient tool for monitoring outcomes of drug treatment and reinfection in opisthorchiasis. Due to the ease of urine sample collection and handling, the urine assay becomes an alternative method to faecal examination for diagnosis and monitoring of opisthorchiasis.

Identifiants

pubmed: 32735672
pii: 5879490
doi: 10.1093/trstmh/traa057
doi:

Substances chimiques

Antigens, Helminth 0
Praziquantel 6490C9U457

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

751-761

Informations de copyright

© The Author(s) 2020. Published by Oxford University Press on behalf of Royal Society of Tropical Medicine and Hygiene.

Auteurs

Chanika Worasith (C)

Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.

Chompunoot Wangboon (C)

School of Preclinical Science, Institute of Science, Suranaree University of Technology, Nakhon Rachasima 30000, Thailand.

Kulthida Y Kopolrat (KY)

Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.

Chutima Homwong (C)

Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.

Jiraporn Sithithaworn (J)

Faculty of Medicine, Mahasarakham University, Mahasarakham 44150, Thailand.

Anchalee Techasen (A)

Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Faculty of Associated Medical Sciences, Khon Kaen University, Khon Kaen 40002, Thailand.

Raynoo Thanan (R)

Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Department of Biochemistry, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.

Narong Khuntikeo (N)

Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.
Department of Surgery, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.

Paiboon Sithithaworn (P)

Department of Parasitology, Faculty of Medicine, Khon Kaen University, Khon Kaen 40002, Thailand.
Cholangiocarcinoma Research Institute, Khon Kaen University, Khon Kaen 40002, Thailand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH